TCGA-BA-A6DL-01A-21R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.520
- MYC_TARGETS_V2+0.520
- OXIDATIVE_PHOSPHORYLATION+0.470
- FATTY_ACID_METABOLISM+0.360
- DNA_REPAIR+0.320
- MTORC1_SIGNALING+0.260
- XENOBIOTIC_METABOLISM+0.180
- G2M_CHECKPOINT+0.150
- PEROXISOME+0.150
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- ANGIOGENESIS-0.520
- HEDGEHOG_SIGNALING-0.400
- UV_RESPONSE_DN-0.360
- WNT_BETA_CATENIN_SIGNALING-0.350
- MYOGENESIS-0.340
- APICAL_JUNCTION-0.330
- KRAS_SIGNALING_UP-0.320
- ALLOGRAFT_REJECTION-0.310
- APICAL_SURFACE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-P3-A5QF-01A-11R-A28V-07 | — | — | 0.922 |
| 2 | C3L-00415 | — | cohortSQ1 | 0.893 |
| 3 | SRR8518448 | — | C | 0.885 |
| 4 | TCGA-5T-A9QA-01A-11R-A41B-07 | — | B | 0.882 |
| 5 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.873 |
| 6 | ERR2278860 | — | — | 0.867 |
| 7 | ERR2208932 | — | — | 0.866 |
| 8 | X6b912c88.db40.4bde.8333.79829f05fade | — | cohortA4 | 0.858 |
| 9 | SRR8518395 | — | E | 0.855 |
| 10 | C3N-03882 | — | cohortSQ2 | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |